Diabetic macular edema: Changing treatment paradigms

Current Opinion in Ophthalmology

Volumn 25, Issue 6, 2014, Pages 502-507

  Arevalo, J Fernando ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b KING KHALED EYE SPECIALIST HOSPITAL   (Saudi Arabia)

Author keywords

Diabetic macular edema; Diabetic retinopathy; Focal grid laser; Intravitreal anti vascular endothelial growth factor; Intravitreal corticosteroids

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

CATARACT EXTRACTION; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; HUMAN; INTRAVITREAL IMPLANT; LOW LEVEL LASER THERAPY; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANTAGONISTS AND INHIBITORS; INTRAVITREAL DRUG ADMINISTRATION; LASER COAGULATION; MACULAR EDEMA; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; PROCEDURES; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84921796235     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0000000000000102     Document Type: Review

References (33)

1. International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation, 2013. http://www.idf.org/diabe tesatlas
2. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998; 105:998-1003.
3. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII: the 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998; 105:1801-1815.
4. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995; 102:647-661.
5. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009; 54:1-32.
6. Roh MI, Kim HS, Song JH, et al. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema. Ophthalmology 2009; 116:80-86.
7. Funatsu H, Yamashita H, Nakamura S, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2006; 113:294-301.
8. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118:615-625.
9. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119:789-801.
10. Muether PS, Droege KM, Fauser S. Vascular endothelial growth factor & suppression times in patients with diabetic macular oedema treated with ranibizumab. Br J Ophthalmol 2014; 98:179-181.
11. Lang GE, Berta A, Eldem BM, et al. RESTORE Extension Study Group. Two-year safety and efficacy of ranibizumab 0.5mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology 2013; 120:2004-2012.
12. Brown DM, Nguyen QD, Marcus DM, et al. RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120:2013-2022.
13. Sivaprasad S, Crosby-Nwaobi R, Esposti S, et al. Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT study (report 4). PLoS One 2013; 8:e72755.
14. Sivaprasad S, Crosby-Nwaobi R, Heng LZ, et al. Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT Report 5). Br J Ophthalmol 2013; 97:1177-1180.
15. Nepomuceno AB, Takaki E, Paes de Almeida FP, et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Am J Ophthalmol 2013; 156:502-510.
16. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113:1695.e1-1695.e15.
17. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117:1064-1077.
18. Ip MS, Domalpally A, Hopkins JJ, et al. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol 2012; 130:1145-1152.
19. Bressler SB, Qin H, Melia M, et al. Diabetic Retinopathy Clinical Research Network. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol 2013; 131:1033-1040.
20. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010; 117:1078-1086; e2.
21. Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DAVINCI study: phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema. Ophthalmology 2011; 118:1819-1826.
22. Bressler SB, Almukhtar T, Aiello LP, et al. Diabetic Retinopathy Clinical Research Network. Green or yellow laser treatment for diabetic macular edema: exploratory assessment within the Diabetic Retinopathy Clinical Research Network. Retina 2013; 33:2080-2088.
23. Callanan DG, Gupta S, Boyer DS, et al. Ozurdex PLACID Study Group. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013; 120:1843-1851.
24. Pollack A, Dotan S, Oliver M. Course of diabetic retinopathy following cataract surgery. Br J Ophthalmol 1991; 75:2-8.
25. Jaffe GJ, Burton TC, Kuhn E, et al. Progression of nonproliferative diabetic retinopathy and visual outcome after extracapsular cataract extraction and intraocular lens implantation. Am J Ophthalmol 1992; 114:448-456.
26. Benson WE, Brown GC, Tasman W, et al. Extracapsular cataract extraction with placement of a posterior chamber lens in patients with diabetic retino-pathy. Ophthalmology 1993; 100:730-738.
27. Baker CW, Almukhtar T, Bressler NM, et al. Diabetic Retinopathy Clinical Research Network Authors/Writing Committee. Macular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edema. JAMA Ophthalmol 2013; 131:870-879.
28. Patel JI, Hykin PG, Cree IA. Diabetic cataract removal: postoperative progression of maculopathy: growth factor and clinical analysis. Br J Ophthalmol 2006; 90:697-701.
29. Cheema RA, Al-Mubarak MM, Amin YM, Cheema MA. Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy: prospective randomized study. J Cataract Refract Surg 2009; 35:18-25.
30. Chae JB, Joe SG, Yang SJ, et al. Effect of combined cataract surgery and ranibizumab injection in postoperative macular edema in nonproliferative diabetic retinopathy. Retina 2014; 34:149-156.
31. Shamsi HN, Masaud JS, Ghazi NG. Diabetic macular edema: new promising therapies. World J Diabetes 2013; 4:324-338.
32. Haller JA, Qin H, Apte RS, et al. Diabetic Retinopathy Clinical Research NetworkWritingCommittee.Vitrectomy outcomesineyes withdiabetic macular edema and vitreomacular traction. Ophthalmology 2010; 117:1087-1093.
33. Diaz-Llopis M, Udaondo P, Millán JM, Arevalo JF. Enzymatic vitrectomy for diabetic retinopathy and diabetic macular edema. World J Diabetes 2013; 4:319-323.